UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients (Q34947658)

5 August 2017

UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients (English)

1 reference

5 August 2017

S E Prausa

1

1 reference

5 August 2017

T Fukuda

2

1 reference

5 August 2017

D Maseck

3

1 reference

5 August 2017

K L Curtsinger

4

1 reference

5 August 2017

C Liu

5

1 reference

5 August 2017

K Zhang

6

1 reference

5 August 2017

T G Nick

7

1 reference

5 August 2017

J R Sherbotie

8

1 reference

5 August 2017

E N Ellis

9

1 reference

5 August 2017

J Goebel

10

1 reference

5 August 2017

A A Vinks

11

1 reference

5 August 2017

language of work or name

English

0 references

publication date

18 February 2009

1 reference

Clinical Pharmacology & Therapeutics

5 August 2017

1 reference

5 August 2017

85

1 reference

5 August 2017

495-500

1 reference

5 August 2017

5

1 reference

Clinical pharmacokinetics of mycophenolate mofetil

5 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Therapeutic drug monitoring of mycophenolate mofetil in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Genetic and nongenetic determinants of between-patient variability in the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Human UDP-glucuronosyltransferases: metabolism, expression, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Identification and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

Extreme discordant phenotype methodology: an intuitive approach to clinical pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

A comparative analysis of the use of mycophenolate mofetil in pediatric vs. adult renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

7 January 2021

Mycophenolate mofetil in pediatric renal transplantation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

7 January 2021

Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

7 January 2021

The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.3

7 January 2021

Identifiers

DOI

10.1038/CLPT.2009.3

1 reference

5 August 2017

1 reference